{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.10.13","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kaggle":{"accelerator":"nvidiaTeslaT4","dataSources":[],"dockerImageVersionId":30699,"isInternetEnabled":true,"language":"python","sourceType":"notebook","isGpuEnabled":true}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"code","source":"import pandas as pd\nimport numpy as np\nfrom datasets import Dataset\nfrom sklearn.model_selection import train_test_split, GridSearchCV\nfrom sklearn.feature_extraction.text import TfidfVectorizer\nfrom sklearn.linear_model import LogisticRegression\nfrom sklearn.svm import SVC\nfrom sklearn.ensemble import RandomForestClassifier\nfrom sklearn.metrics import accuracy_score, f1_score, classification_report, confusion_matrix\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport warnings","metadata":{"_uuid":"8f2839f25d086af736a60e9eeb907d3b93b6e0e5","_cell_guid":"b1076dfc-b9ad-4769-8c92-a6c4dae69d19","execution":{"iopub.status.busy":"2024-05-18T14:31:28.220230Z","iopub.execute_input":"2024-05-18T14:31:28.220494Z","iopub.status.idle":"2024-05-18T14:31:31.520971Z","shell.execute_reply.started":"2024-05-18T14:31:28.220468Z","shell.execute_reply":"2024-05-18T14:31:31.519980Z"},"trusted":true},"execution_count":1,"outputs":[]},{"cell_type":"code","source":"from datasets import load_dataset\n\ntry:\n    # Load the dataset\n    dataset = load_dataset(\"medalpaca/medical_meadow_medical_flashcards\")\n    print(dataset)\n\n    # Save the dataset to disk\n    save_path = '/kaggle/working/medical_meadow_dataset'\n    dataset.save_to_disk(save_path)\n    print(f\"Dataset saved successfully to {save_path}\")\nexcept Exception as e:\n    print(f\"An error occurred: {e}\")","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:33:10.147315Z","iopub.execute_input":"2024-05-18T14:33:10.147781Z","iopub.status.idle":"2024-05-18T14:33:11.195768Z","shell.execute_reply.started":"2024-05-18T14:33:10.147749Z","shell.execute_reply":"2024-05-18T14:33:11.194699Z"},"trusted":true},"execution_count":3,"outputs":[{"name":"stdout","text":"DatasetDict({\n    train: Dataset({\n        features: ['instruction', 'input', 'output'],\n        num_rows: 33955\n    })\n})\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"Saving the dataset (0/1 shards):   0%|          | 0/33955 [00:00<?, ? examples/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3674127adeae41b88a26e4c25494aa00"}},"metadata":{}},{"name":"stdout","text":"Dataset saved successfully to /kaggle/working/medical_meadow_dataset\n","output_type":"stream"}]},{"cell_type":"code","source":"# Suppress warnings\nwarnings.filterwarnings(\"ignore\", category=UserWarning, module='sklearn')","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:33:38.016744Z","iopub.execute_input":"2024-05-18T14:33:38.017145Z","iopub.status.idle":"2024-05-18T14:33:38.021781Z","shell.execute_reply.started":"2024-05-18T14:33:38.017117Z","shell.execute_reply":"2024-05-18T14:33:38.020702Z"},"trusted":true},"execution_count":4,"outputs":[]},{"cell_type":"code","source":"# Load the dataset from the saved arrow file\ndataset = Dataset.from_file('/kaggle/working/medical_meadow_dataset/train/data-00000-of-00001.arrow')\n\n# Convert to Pandas DataFrame for analysis\ndf = dataset.to_pandas()","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:34:00.334724Z","iopub.execute_input":"2024-05-18T14:34:00.335358Z","iopub.status.idle":"2024-05-18T14:34:00.391300Z","shell.execute_reply.started":"2024-05-18T14:34:00.335325Z","shell.execute_reply":"2024-05-18T14:34:00.390558Z"},"trusted":true},"execution_count":5,"outputs":[]},{"cell_type":"code","source":"# Prepare the data for training\nX = df['input']\ny = df['output']","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:34:05.929996Z","iopub.execute_input":"2024-05-18T14:34:05.930582Z","iopub.status.idle":"2024-05-18T14:34:05.936446Z","shell.execute_reply.started":"2024-05-18T14:34:05.930548Z","shell.execute_reply":"2024-05-18T14:34:05.935398Z"},"trusted":true},"execution_count":6,"outputs":[]},{"cell_type":"code","source":"# Filter out classes with less than 2 instances\nclass_counts = y.value_counts()\nvalid_classes = class_counts[class_counts >= 2].index\nfiltered_df = df[df['output'].isin(valid_classes)]","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:36:35.649963Z","iopub.execute_input":"2024-05-18T14:36:35.650349Z","iopub.status.idle":"2024-05-18T14:36:35.692492Z","shell.execute_reply.started":"2024-05-18T14:36:35.650322Z","shell.execute_reply":"2024-05-18T14:36:35.691801Z"},"trusted":true},"execution_count":10,"outputs":[]},{"cell_type":"code","source":"# Update X and y after filtering\nX = filtered_df['input']\ny = filtered_df['output']","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:36:44.847685Z","iopub.execute_input":"2024-05-18T14:36:44.848570Z","iopub.status.idle":"2024-05-18T14:36:44.852740Z","shell.execute_reply.started":"2024-05-18T14:36:44.848515Z","shell.execute_reply":"2024-05-18T14:36:44.851850Z"},"trusted":true},"execution_count":11,"outputs":[]},{"cell_type":"code","source":"# Split the data into training and testing sets\nX_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state=42)","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:36:57.721398Z","iopub.execute_input":"2024-05-18T14:36:57.722102Z","iopub.status.idle":"2024-05-18T14:36:57.730333Z","shell.execute_reply.started":"2024-05-18T14:36:57.722069Z","shell.execute_reply":"2024-05-18T14:36:57.729157Z"},"trusted":true},"execution_count":12,"outputs":[]},{"cell_type":"code","source":"# Convert text data to TF-IDF features\nvectorizer = TfidfVectorizer(max_features=5000, ngram_range=(1, 2), stop_words='english')\nX_train_tfidf = vectorizer.fit_transform(X_train)\nX_test_tfidf = vectorizer.transform(X_test)","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:37:06.232176Z","iopub.execute_input":"2024-05-18T14:37:06.233246Z","iopub.status.idle":"2024-05-18T14:37:06.268454Z","shell.execute_reply.started":"2024-05-18T14:37:06.233202Z","shell.execute_reply":"2024-05-18T14:37:06.267718Z"},"trusted":true},"execution_count":13,"outputs":[]},{"cell_type":"code","source":"# Define hyperparameter grids for different models\nparam_grids = {\n    'logistic_regression': {\n        'C': [0.1, 1, 10],\n        'solver': ['liblinear', 'saga'],\n        'penalty': ['l1', 'l2']\n    },\n    'svm': {\n        'C': [0.1, 1, 10],\n        'kernel': ['linear', 'rbf'],\n        'gamma': ['scale', 'auto']\n    },\n    'random_forest': {\n        'n_estimators': [10, 50, 100],\n        'max_depth': [None, 5, 10],\n        'min_samples_split': [2, 5, 10]\n    }\n}","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:37:16.639689Z","iopub.execute_input":"2024-05-18T14:37:16.640591Z","iopub.status.idle":"2024-05-18T14:37:16.646243Z","shell.execute_reply.started":"2024-05-18T14:37:16.640515Z","shell.execute_reply":"2024-05-18T14:37:16.645365Z"},"trusted":true},"execution_count":14,"outputs":[]},{"cell_type":"code","source":"# Train and evaluate models\nresults = {}\nfor model_name, param_grid in param_grids.items():\n    if model_name == 'logistic_regression':\n        model = LogisticRegression(max_iter=1000)\n    elif model_name == 'svm':\n        model = SVC()\n    elif model_name == 'random_forest':\n        model = RandomForestClassifier()\n    \n    clf = GridSearchCV(model, param_grid, cv=5, scoring='f1_macro', n_jobs=-1)\n    clf.fit(X_train_tfidf, y_train)\n    \n    y_pred = clf.predict(X_test_tfidf)\n    accuracy = accuracy_score(y_test, y_pred)\n    f1 = f1_score(y_test, y_pred, average='macro')\n    results[model_name] = {'accuracy': accuracy, 'f1': f1, 'best_params': clf.best_params_, 'y_pred': y_pred}","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:37:26.529874Z","iopub.execute_input":"2024-05-18T14:37:26.530217Z","iopub.status.idle":"2024-05-18T14:38:52.941806Z","shell.execute_reply.started":"2024-05-18T14:37:26.530190Z","shell.execute_reply":"2024-05-18T14:38:52.940616Z"},"trusted":true},"execution_count":15,"outputs":[{"name":"stderr","text":"/opt/conda/lib/python3.10/site-packages/sklearn/svm/_base.py:1244: ConvergenceWarning: Liblinear failed to converge, increase the number of iterations.\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/svm/_base.py:1244: ConvergenceWarning: Liblinear failed to converge, increase the number of iterations.\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/svm/_base.py:1244: ConvergenceWarning: Liblinear failed to converge, increase the number of iterations.\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/svm/_base.py:1244: ConvergenceWarning: Liblinear failed to converge, increase the number of iterations.\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/svm/_base.py:1244: ConvergenceWarning: Liblinear failed to converge, increase the number of iterations.\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/linear_model/_sag.py:350: ConvergenceWarning: The max_iter was reached which means the coef_ did not converge\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/linear_model/_sag.py:350: ConvergenceWarning: The max_iter was reached which means the coef_ did not converge\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/linear_model/_sag.py:350: ConvergenceWarning: The max_iter was reached which means the coef_ did not converge\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/linear_model/_sag.py:350: ConvergenceWarning: The max_iter was reached which means the coef_ did not converge\n  warnings.warn(\n/opt/conda/lib/python3.10/site-packages/sklearn/linear_model/_sag.py:350: ConvergenceWarning: The max_iter was reached which means the coef_ did not converge\n  warnings.warn(\n","output_type":"stream"}]},{"cell_type":"code","source":"# Print results\nfor model_name, result in results.items():\n    print(f\"Model: {model_name}\")\n    print(f\"Accuracy: {result['accuracy']:.2f}\")\n    print(f\"F1-score: {result['f1']:.2f}\")\n    print(f\"Best hyperparameters: {result['best_params']}\")\n    print()\n    \n    # Detailed evaluation\n    print(\"Classification Report:\")\n    print(classification_report(y_test, result['y_pred']))\n    \n    # Confusion Matrix\n    conf_matrix = confusion_matrix(y_test, result['y_pred'])\n    plt.figure(figsize=(12, 8))\n    sns.heatmap(conf_matrix, annot=True, fmt='d', cmap='Blues')\n    plt.title(f'Confusion Matrix for {model_name}')\n    plt.xlabel('Predicted')\n    plt.ylabel('Actual')\n    plt.show()","metadata":{"execution":{"iopub.status.busy":"2024-05-18T14:40:51.028200Z","iopub.execute_input":"2024-05-18T14:40:51.029114Z","iopub.status.idle":"2024-05-18T14:41:22.407297Z","shell.execute_reply.started":"2024-05-18T14:40:51.029076Z","shell.execute_reply":"2024-05-18T14:41:22.406330Z"},"trusted":true},"execution_count":16,"outputs":[{"name":"stdout","text":"Model: logistic_regression\nAccuracy: 0.73\nF1-score: 0.44\nBest hyperparameters: {'C': 10, 'penalty': 'l1', 'solver': 'saga'}\n\nClassification Report:\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 precision    recall  f1-score   support\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.82      1.00      0.90        83\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     A complication that may occur 3-5 days after a myocardial infarction is papillary muscle rupture, which often causes mitral regurgitation.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adenocarcinoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Anti-müllerian hormone causes atrophy of the müllerian ducts, which would have developed into the female internal genital tract.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Bence Jones proteinuria is a medical condition characterized by the presence of free light chain excretion in the urine. It is commonly associated with multiple myeloma, which is a type of cancer affecting plasma cells in the bone marrow.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Bethanechol is a cholinomimetic agent that is commonly used to treat post-operative and neurogenic ileus.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Bosentan is a medication that acts as a competitive endothelin-1 receptor antagonist. It is primarily used to treat pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. By blocking the action of endothelin-1, a potent vasoconstrictor that contributes to the development of pulmonary hypertension, bosentan helps to dilate the blood vessels and improve blood flow in the lungs. This can alleviate symptoms and improve exercise capacity in patients with pulmonary hypertension.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Brugada syndrome is associated with an ECG pattern of pseudo-right bundle branch block and ST elevations in leads V1 - V3.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Brugada syndrome is characterized by an ECG pattern of pseudo-right bundle branch block and ST elevations in leads V1 - V3.       0.00      0.00      0.00         1\nCT angiography is considered the preferred diagnostic study for suspected aortic dissection in hemodynamically stable patients with normal renal function.\n\nAortic dissection is a serious medical condition in which there is a tear in the inner layer of the aorta, the largest artery in the body. If left untreated, aortic dissection can lead to life-threatening complications. Therefore, prompt diagnosis and treatment are essential.\n\nIn hemodynamically stable patients with normal renal function who are suspected of having an aortic dissection, CT angiography is considered the preferred diagnostic test. CT angiography involves injecting a contrast dye into the patient's bloodstream and then using a CT scanner to create detailed images of the aorta and surrounding blood vessels. This test is highly sensitive and specific for detecting aortic dissection and can provide important information about the location and extent of the tear.\n\nOther diagnostic tests for aortic dissection include echocardiography, MRI, and aortography. However, CT angiography is generally considered the preferred method due to its high accuracy, noninvasiveness, and ability to provide rapid results.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Campylobacter jejuni is a curved bacteria that causes inflammatory diarrhea. The diarrhea is initially watery and ill-smelling, and can progress to bloody diarrhea.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Deferoxamine, deferasirox, and deferiprone are iron chelators.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Diseases characterized by increased cell turnover, such as leukemia and myeloproliferative disorders, are often associated with the development of uric acid kidney stones.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Entecavir, tenofovir, and PEG-IFN-alpha can be used to treat HBV.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Eosinophils.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Focal segmental glomerulosclerosis (FSGS).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                HIV testing should be offered to a patient with these symptoms.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Hemolytic uremic syndrome is a condition that is classically seen in children with E. coli O157:H7 dysentery, which results from exposure to undercooked beef.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Loop diuretics induce expression of COX-2, which leads to synthesis of prostaglandins (e.g. PGE).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Lower motor neuron lesions of the facial nerve result in ipsi-lateral paralysis of the upper and lower muscles of facial expression.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Lymphoblasts are immature lymphocytes. Positive nuclear staining for TdT in these cells is significant because TdT is a DNA polymerase that is present during the early stages of B and T cell development.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  M1 muscarinic antagonists, such as Benztropine, can reduce pill rolling tremors and cogwheel rigidity in Parkinson's disease.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Membranous nephropathy is a kidney disorder that is characterized by the presence of subepithelial deposits. These deposits have a distinct 'spike and dome' appearance when viewed under electron microscopy.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Membranous nephropathy.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Mycoplasma pneumoniae is a type of bacteria that is commonly associated with I M cold agglutination of red blood cells.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Nitroprusside causes vasodilation via nitric oxide, which is useful during the treatment of hypertensive emergency.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Non-bacterial thrombotic endocarditis is a condition characterized by the formation of sterile vegetations on heart valves. This condition can be caused by a hypercoagulable state or an underlying adenocarcinoma.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Normal levels of angiotensin II can cause an increase in GFR.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      One clinical feature of aortic regurgitation involves hyperdynamic circulation due to increased (widened) pulse pressure.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Pancreatic adenocarcinoma is associated with the serum tumor markers CA 19-9 and CEA (less specific).       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Patients with hairy cell leukemia typically present with massive splenomegaly due to expansion of the red pulp.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Patients with obsessive-compulsive personality disorder are ego syntonic, which means their behavior is consistent with their own beliefs or attitudes.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Patients with protein C or S deficiency are at an increased risk of developing thrombotic skin necrosis when receiving warfarin therapy. Thrombotic skin necrosis is a rare but serious complication of warfarin therapy that can result in the formation of blood clots in the small blood vessels of the skin, leading to tissue damage and potential hemorrhage. Protein C and S are natural anticoagulants that help regulate blood clotting, and deficiencies in these proteins can lead to an increased risk of thrombosis. Therefore, patients with protein C or S deficiency should be closely monitored when receiving warfarin therapy to prevent this complication.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phenylalanine can be converted to tyrosine via the enzyme phenylalanine hydroxylase, which requires tetrahydrobiopterin as a cofactor. This conversion is an important step in the biosynthesis of tyrosine, which is an essential amino acid that plays a critical role in protein synthesis and other metabolic processes in the body.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Pneumocystis pneumonia is an AIDS-defining illness that presents with a CD4+ count < 200.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sturge-Weber syndrome is a rare neurological disorder that is characterized by abnormal blood vessels on the surface of the brain and skin. It can cause symptoms such as seizures, intellectual disability, and glaucoma. Another name for this condition is encephalotrigeminal angiomatosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Suramin and Melarsoprol are medications that can be used to treat Trypanosoma brucei, a parasitic infection that causes African sleeping sickness. These medications work by targeting the parasite and inhibiting its ability to replicate and spread throughout the body. They are typically administered under the supervision of a healthcare professional and may be used in combination with other medications to treat the infection.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Tetracyclines inhibit bacterial protein synthesis by binding to the 30s subunit of ribosomes, which prevents the attachment of aminoacyl-tRNA.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The AFP levels would be decreased.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The classic presentation of hemochromatosis includes a triad of cirrhosis, diabetes mellitus, and bronze skin.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          The first generation cephalosporins include cephalexin and cefazolin.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The likely diagnosis for the patient's condition is G6PD deficiency.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The likely diagnosis for the patient's condition is a stress fracture.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The likely diagnosis for the patient's condition is androgen insensitivity syndrome, a genetic disorder in which the body is unable to respond to androgens, resulting in impaired virilization and development of male sex characteristics. In individuals with complete androgen insensitivity syndrome, the external genitalia appear female, but the internal reproductive organs are absent or underdeveloped.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The likely diagnosis for the patient's condition is ankylosing spondylitis.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The likely diagnosis for the patient's condition is autosomal dominant polycystic kidney disease (PKD).       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The likely diagnosis for the patient's condition is coarctation of the aorta.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The likely diagnosis for the patient's condition is colonic pseudo-obstruction, also known as Ogilvie syndrome.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The likely diagnosis for the patient's condition is diabetic ketoacidosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The likely diagnosis for the patient's condition is systemic lupus erythematosus (SLE).       0.20      1.00      0.33         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mnemonic caNNOT is used to remember the toxicities associated with aminoglycoside antibiotics. It stands for Nephrotoxicity, Neuromuscular blockade, Ototoxicity, and Teratogen (specifically, deafness in neonates).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The most common cause of mitral regurgitation in developed countries is mitral valve prolapse.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The term used to describe this type of disease prevention is secondary.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The type of leukemia that is commonly associated with Down syndrome is acute lymphoblastic leukemia, and it typically occurs after the age of 5 years.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The virulence factor that is commonly found in these three bacterial species is IgA protease. This enzyme is capable of cleaving immunoglobulin A (IgA), which is an important component of the body's immune system, and can help these bacteria evade the host's immune response.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Thiazide diuretics block the Na+-Cl- cotransporter on the luminal membrane of the DCT.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Thiazide diuretics can be used to prevent calcium kidney stones.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Thiazide diuretics may be useful in the treatment of nephrogenic diabetes insipidus.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Thiazide diuretics may cause hypo-natremia as an adverse effect.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Thiazide diuretics stimulate the reabsorption of Ca2+ in the distal tubule of the kidney.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Thrombotic thrombocytopenic purpura (TTP) is caused by inhibition or deficiency of the ADAMTS13 (vWF metalloprotease) enzyme.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tizanidine is an α2 agonist that may be used as a muscle relaxant.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Topiramate is an anti-epileptic associated with weight loss.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Trazodone is an atypical antidepressant that is primarily used to treat insomnia.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tumor Lysis Syndrome is most commonly associated with the treatment of lymphomas and acute lymphoblastic leukemia.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Type I collagen.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Upper motoneuron lesions may cause hyper-reflexia.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                     Urge incontinence is a type of urinary incontinence that can be managed with various treatment options. One common approach is the use of medications known as anti-muscarinics, which work by blocking certain nerve signals that can cause the bladder to contract uncontrollably. Examples of anti-muscarinic medications that may be prescribed for urge incontinence include oxybutynin, tolterodine, and solifenacin. Other potential treatment options for urge incontinence may include bladder training exercises, pelvic floor muscle exercises, and lifestyle modifications such as dietary changes and fluid management. The specific treatment plan that is recommended may depend on various factors, including the severity of symptoms, the underlying cause of the condition, and the individual's overall health status.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Wilms tumor, also known as nephroblastoma, typically presents with these features.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Wilson disease is caused by an autosomal recessive defect in ATP-mediated hepatocyte copper transport.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Wilson disease may be treated with oral zinc or chelating agents (e.g. penicillamine, trientine).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Yes.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Zollinger-Ellison syndrome is diagnosed with a positive secretin stimulation test.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    α-adrenergic agonists cause K+ to shift out of cells, causing hyperkalemia.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        α-methyldopa is an α2 agonist that is primarily used to treat gestational hypertension.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  α-methyldopa.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      α-thalassemia with a cis deletion is more prevalent in Asian populations.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-blockers may cause unopposed α1 agonism if given alone for cocaine toxicity or pheochromocytoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        β-thalassemia is most commonly seen in individuals of African or Mediterranean descent.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-thalassemia is usually caused by gene mutations.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           β-thalassemia mutations in β-globin genes result in absent (β0) or diminished (β+) production of the β-globin chain.       1.00      1.00      1.00         1\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       accuracy                           0.73       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      macro avg       0.43      0.46      0.44       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   weighted avg       0.63      0.73      0.68       162\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<Figure size 1200x800 with 2 Axes>","image/png":"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"},"metadata":{}},{"name":"stdout","text":"Model: svm\nAccuracy: 0.80\nF1-score: 0.63\nBest hyperparameters: {'C': 10, 'gamma': 'scale', 'kernel': 'linear'}\n\nClassification Report:\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 precision    recall  f1-score   support\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.75      1.00      0.86        83\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     A complication that may occur 3-5 days after a myocardial infarction is papillary muscle rupture, which often causes mitral regurgitation.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adenocarcinoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Anti-müllerian hormone causes atrophy of the müllerian ducts, which would have developed into the female internal genital tract.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Bence Jones proteinuria is a medical condition characterized by the presence of free light chain excretion in the urine. It is commonly associated with multiple myeloma, which is a type of cancer affecting plasma cells in the bone marrow.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Bosentan is a medication that acts as a competitive endothelin-1 receptor antagonist. It is primarily used to treat pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. By blocking the action of endothelin-1, a potent vasoconstrictor that contributes to the development of pulmonary hypertension, bosentan helps to dilate the blood vessels and improve blood flow in the lungs. This can alleviate symptoms and improve exercise capacity in patients with pulmonary hypertension.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Brugada syndrome is associated with an ECG pattern of pseudo-right bundle branch block and ST elevations in leads V1 - V3.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Brugada syndrome is characterized by an ECG pattern of pseudo-right bundle branch block and ST elevations in leads V1 - V3.       0.00      0.00      0.00         1\nCT angiography is considered the preferred diagnostic study for suspected aortic dissection in hemodynamically stable patients with normal renal function.\n\nAortic dissection is a serious medical condition in which there is a tear in the inner layer of the aorta, the largest artery in the body. If left untreated, aortic dissection can lead to life-threatening complications. Therefore, prompt diagnosis and treatment are essential.\n\nIn hemodynamically stable patients with normal renal function who are suspected of having an aortic dissection, CT angiography is considered the preferred diagnostic test. CT angiography involves injecting a contrast dye into the patient's bloodstream and then using a CT scanner to create detailed images of the aorta and surrounding blood vessels. This test is highly sensitive and specific for detecting aortic dissection and can provide important information about the location and extent of the tear.\n\nOther diagnostic tests for aortic dissection include echocardiography, MRI, and aortography. However, CT angiography is generally considered the preferred method due to its high accuracy, noninvasiveness, and ability to provide rapid results.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Campylobacter jejuni is a curved bacteria that causes inflammatory diarrhea. The diarrhea is initially watery and ill-smelling, and can progress to bloody diarrhea.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Deferoxamine, deferasirox, and deferiprone are iron chelators.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Diseases characterized by increased cell turnover, such as leukemia and myeloproliferative disorders, are often associated with the development of uric acid kidney stones.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Entecavir, tenofovir, and PEG-IFN-alpha can be used to treat HBV.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Eosinophils.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Focal segmental glomerulosclerosis (FSGS).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                HIV testing should be offered to a patient with these symptoms.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Hemolytic uremic syndrome is a condition that is classically seen in children with E. coli O157:H7 dysentery, which results from exposure to undercooked beef.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Loop diuretics induce expression of COX-2, which leads to synthesis of prostaglandins (e.g. PGE).       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Lower motor neuron lesions of the facial nerve result in ipsi-lateral paralysis of the upper and lower muscles of facial expression.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Lymphoblasts are immature lymphocytes. Positive nuclear staining for TdT in these cells is significant because TdT is a DNA polymerase that is present during the early stages of B and T cell development.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  M1 muscarinic antagonists, such as Benztropine, can reduce pill rolling tremors and cogwheel rigidity in Parkinson's disease.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Membranous nephropathy is a kidney disorder that is characterized by the presence of subepithelial deposits. These deposits have a distinct 'spike and dome' appearance when viewed under electron microscopy.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Membranous nephropathy.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Mycoplasma pneumoniae is a type of bacteria that is commonly associated with I M cold agglutination of red blood cells.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Nitroprusside causes vasodilation via nitric oxide, which is useful during the treatment of hypertensive emergency.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Non-bacterial thrombotic endocarditis is a condition characterized by the formation of sterile vegetations on heart valves. This condition can be caused by a hypercoagulable state or an underlying adenocarcinoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Normal levels of angiotensin II can cause an increase in GFR.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      One clinical feature of aortic regurgitation involves hyperdynamic circulation due to increased (widened) pulse pressure.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Pancreatic adenocarcinoma is associated with the serum tumor markers CA 19-9 and CEA (less specific).       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Patients with hairy cell leukemia typically present with massive splenomegaly due to expansion of the red pulp.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Patients with obsessive-compulsive personality disorder are ego syntonic, which means their behavior is consistent with their own beliefs or attitudes.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Patients with protein C or S deficiency are at an increased risk of developing thrombotic skin necrosis when receiving warfarin therapy. Thrombotic skin necrosis is a rare but serious complication of warfarin therapy that can result in the formation of blood clots in the small blood vessels of the skin, leading to tissue damage and potential hemorrhage. Protein C and S are natural anticoagulants that help regulate blood clotting, and deficiencies in these proteins can lead to an increased risk of thrombosis. Therefore, patients with protein C or S deficiency should be closely monitored when receiving warfarin therapy to prevent this complication.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phenylalanine can be converted to tyrosine via the enzyme phenylalanine hydroxylase, which requires tetrahydrobiopterin as a cofactor. This conversion is an important step in the biosynthesis of tyrosine, which is an essential amino acid that plays a critical role in protein synthesis and other metabolic processes in the body.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Pneumocystis pneumonia is an AIDS-defining illness that presents with a CD4+ count < 200.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sturge-Weber syndrome is a rare neurological disorder that is characterized by abnormal blood vessels on the surface of the brain and skin. It can cause symptoms such as seizures, intellectual disability, and glaucoma. Another name for this condition is encephalotrigeminal angiomatosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Suramin and Melarsoprol are medications that can be used to treat Trypanosoma brucei, a parasitic infection that causes African sleeping sickness. These medications work by targeting the parasite and inhibiting its ability to replicate and spread throughout the body. They are typically administered under the supervision of a healthcare professional and may be used in combination with other medications to treat the infection.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Tetracyclines inhibit bacterial protein synthesis by binding to the 30s subunit of ribosomes, which prevents the attachment of aminoacyl-tRNA.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The AFP levels would be decreased.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The classic presentation of hemochromatosis includes a triad of cirrhosis, diabetes mellitus, and bronze skin.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          The first generation cephalosporins include cephalexin and cefazolin.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The likely diagnosis for the patient's condition is G6PD deficiency.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The likely diagnosis for the patient's condition is a stress fracture.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The likely diagnosis for the patient's condition is androgen insensitivity syndrome, a genetic disorder in which the body is unable to respond to androgens, resulting in impaired virilization and development of male sex characteristics. In individuals with complete androgen insensitivity syndrome, the external genitalia appear female, but the internal reproductive organs are absent or underdeveloped.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The likely diagnosis for the patient's condition is ankylosing spondylitis.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The likely diagnosis for the patient's condition is colonic pseudo-obstruction, also known as Ogilvie syndrome.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The likely diagnosis for the patient's condition is diabetic ketoacidosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The likely diagnosis for the patient's condition is systemic lupus erythematosus (SLE).       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mnemonic caNNOT is used to remember the toxicities associated with aminoglycoside antibiotics. It stands for Nephrotoxicity, Neuromuscular blockade, Ototoxicity, and Teratogen (specifically, deafness in neonates).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The most common cause of mitral regurgitation in developed countries is mitral valve prolapse.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The term used to describe this type of disease prevention is secondary.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The type of leukemia that is commonly associated with Down syndrome is acute lymphoblastic leukemia, and it typically occurs after the age of 5 years.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The virulence factor that is commonly found in these three bacterial species is IgA protease. This enzyme is capable of cleaving immunoglobulin A (IgA), which is an important component of the body's immune system, and can help these bacteria evade the host's immune response.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Thiazide diuretics block the Na+-Cl- cotransporter on the luminal membrane of the DCT.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Thiazide diuretics can be used to prevent calcium kidney stones.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Thiazide diuretics may be useful in the treatment of nephrogenic diabetes insipidus.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Thiazide diuretics may cause hypo-natremia as an adverse effect.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Thiazide diuretics stimulate the reabsorption of Ca2+ in the distal tubule of the kidney.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Thrombotic thrombocytopenic purpura (TTP) is caused by inhibition or deficiency of the ADAMTS13 (vWF metalloprotease) enzyme.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tizanidine is an α2 agonist that may be used as a muscle relaxant.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Topiramate is an anti-epileptic associated with weight loss.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tumor Lysis Syndrome is most commonly associated with the treatment of lymphomas and acute lymphoblastic leukemia.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Type I collagen.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Upper motoneuron lesions may cause hyper-reflexia.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Wilms tumor, also known as nephroblastoma, typically presents with these features.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Wilson disease is caused by an autosomal recessive defect in ATP-mediated hepatocyte copper transport.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Wilson disease may be treated with oral zinc or chelating agents (e.g. penicillamine, trientine).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Zollinger-Ellison syndrome is diagnosed with a positive secretin stimulation test.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        α-methyldopa is an α2 agonist that is primarily used to treat gestational hypertension.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  α-methyldopa.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-blockers may cause unopposed α1 agonism if given alone for cocaine toxicity or pheochromocytoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        β-thalassemia is most commonly seen in individuals of African or Mediterranean descent.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-thalassemia is usually caused by gene mutations.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           β-thalassemia mutations in β-globin genes result in absent (β0) or diminished (β+) production of the β-globin chain.       1.00      1.00      1.00         1\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       accuracy                           0.80       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      macro avg       0.62      0.64      0.63       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   weighted avg       0.66      0.80      0.72       162\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<Figure size 1200x800 with 2 Axes>","image/png":"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"},"metadata":{}},{"name":"stdout","text":"Model: random_forest\nAccuracy: 0.73\nF1-score: 0.44\nBest hyperparameters: {'max_depth': None, 'min_samples_split': 2, 'n_estimators': 100}\n\nClassification Report:\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 precision    recall  f1-score   support\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.77      1.00      0.87        83\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     A complication that may occur 3-5 days after a myocardial infarction is papillary muscle rupture, which often causes mitral regurgitation.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adenocarcinoma of the lung is a type of lung cancer that is often associated with activating mutations in the KRAS, EGFR, and ALK genes. These mutations can cause the cells in the lung tissue to grow and divide uncontrollably, leading to the development of cancerous tumors. While other types of lung cancer may also have genetic mutations, adenocarcinoma is particularly associated with these specific mutations. It is important to note that not all individuals with adenocarcinoma will have these mutations, and other factors may also contribute to the development of the disease.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adenocarcinoma.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Anti-müllerian hormone causes atrophy of the müllerian ducts, which would have developed into the female internal genital tract.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Bence Jones proteinuria is a medical condition characterized by the presence of free light chain excretion in the urine. It is commonly associated with multiple myeloma, which is a type of cancer affecting plasma cells in the bone marrow.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Bethanechol is a cholinomimetic agent that is commonly used to treat post-operative and neurogenic ileus.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Bosentan is a medication that acts as a competitive endothelin-1 receptor antagonist. It is primarily used to treat pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. By blocking the action of endothelin-1, a potent vasoconstrictor that contributes to the development of pulmonary hypertension, bosentan helps to dilate the blood vessels and improve blood flow in the lungs. This can alleviate symptoms and improve exercise capacity in patients with pulmonary hypertension.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Brugada syndrome is characterized by an ECG pattern of pseudo-right bundle branch block and ST elevations in leads V1 - V3.       0.00      0.00      0.00         1\nCT angiography is considered the preferred diagnostic study for suspected aortic dissection in hemodynamically stable patients with normal renal function.\n\nAortic dissection is a serious medical condition in which there is a tear in the inner layer of the aorta, the largest artery in the body. If left untreated, aortic dissection can lead to life-threatening complications. Therefore, prompt diagnosis and treatment are essential.\n\nIn hemodynamically stable patients with normal renal function who are suspected of having an aortic dissection, CT angiography is considered the preferred diagnostic test. CT angiography involves injecting a contrast dye into the patient's bloodstream and then using a CT scanner to create detailed images of the aorta and surrounding blood vessels. This test is highly sensitive and specific for detecting aortic dissection and can provide important information about the location and extent of the tear.\n\nOther diagnostic tests for aortic dissection include echocardiography, MRI, and aortography. However, CT angiography is generally considered the preferred method due to its high accuracy, noninvasiveness, and ability to provide rapid results.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Campylobacter jejuni is a curved bacteria that causes inflammatory diarrhea. The diarrhea is initially watery and ill-smelling, and can progress to bloody diarrhea.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Deferoxamine, deferasirox, and deferiprone are iron chelators.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Diseases characterized by increased cell turnover, such as leukemia and myeloproliferative disorders, are often associated with the development of uric acid kidney stones.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Entecavir, tenofovir, and PEG-IFN-alpha can be used to treat HBV.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Eosinophils.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Focal segmental glomerulosclerosis (FSGS).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                HIV testing should be offered to a patient with these symptoms.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Hemolytic uremic syndrome is a condition that is classically seen in children with E. coli O157:H7 dysentery, which results from exposure to undercooked beef.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Loop diuretics induce expression of COX-2, which leads to synthesis of prostaglandins (e.g. PGE).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Lower motor neuron lesions of the facial nerve result in ipsi-lateral paralysis of the upper and lower muscles of facial expression.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Lymphoblasts are immature lymphocytes. Positive nuclear staining for TdT in these cells is significant because TdT is a DNA polymerase that is present during the early stages of B and T cell development.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  M1 muscarinic antagonists, such as Benztropine, can reduce pill rolling tremors and cogwheel rigidity in Parkinson's disease.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Membranous nephropathy is a kidney disorder that is characterized by the presence of subepithelial deposits. These deposits have a distinct 'spike and dome' appearance when viewed under electron microscopy.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Membranous nephropathy.       0.50      1.00      0.67         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Mycoplasma pneumoniae is a type of bacteria that is commonly associated with I M cold agglutination of red blood cells.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Nimodipine is a Ca2+ channel blocker that is used to prevent cerebral vasospasm following a subarachnoid hemorrhage.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Nitroprusside causes vasodilation via nitric oxide, which is useful during the treatment of hypertensive emergency.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Non-bacterial thrombotic endocarditis is a condition characterized by the formation of sterile vegetations on heart valves. This condition can be caused by a hypercoagulable state or an underlying adenocarcinoma.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Normal levels of angiotensin II can cause an increase in GFR.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      One clinical feature of aortic regurgitation involves hyperdynamic circulation due to increased (widened) pulse pressure.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Pancreatic adenocarcinoma is associated with the serum tumor markers CA 19-9 and CEA (less specific).       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Patients with hairy cell leukemia typically present with massive splenomegaly due to expansion of the red pulp.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Patients with obsessive-compulsive personality disorder are ego syntonic, which means their behavior is consistent with their own beliefs or attitudes.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Patients with protein C or S deficiency are at an increased risk of developing thrombotic skin necrosis when receiving warfarin therapy. Thrombotic skin necrosis is a rare but serious complication of warfarin therapy that can result in the formation of blood clots in the small blood vessels of the skin, leading to tissue damage and potential hemorrhage. Protein C and S are natural anticoagulants that help regulate blood clotting, and deficiencies in these proteins can lead to an increased risk of thrombosis. Therefore, patients with protein C or S deficiency should be closely monitored when receiving warfarin therapy to prevent this complication.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Phenylalanine can be converted to tyrosine via the enzyme phenylalanine hydroxylase, which requires tetrahydrobiopterin as a cofactor. This conversion is an important step in the biosynthesis of tyrosine, which is an essential amino acid that plays a critical role in protein synthesis and other metabolic processes in the body.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Pneumocystis pneumonia is an AIDS-defining illness that presents with a CD4+ count < 200.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sturge-Weber syndrome is a rare neurological disorder that is characterized by abnormal blood vessels on the surface of the brain and skin. It can cause symptoms such as seizures, intellectual disability, and glaucoma. Another name for this condition is encephalotrigeminal angiomatosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Suramin and Melarsoprol are medications that can be used to treat Trypanosoma brucei, a parasitic infection that causes African sleeping sickness. These medications work by targeting the parasite and inhibiting its ability to replicate and spread throughout the body. They are typically administered under the supervision of a healthcare professional and may be used in combination with other medications to treat the infection.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Tetracyclines inhibit bacterial protein synthesis by binding to the 30s subunit of ribosomes, which prevents the attachment of aminoacyl-tRNA.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The AFP levels would be decreased.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The classic presentation of hemochromatosis includes a triad of cirrhosis, diabetes mellitus, and bronze skin.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          The first generation cephalosporins include cephalexin and cefazolin.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The likely diagnosis for the patient's condition is G6PD deficiency.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The likely diagnosis for the patient's condition is a stress fracture.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The likely diagnosis for the patient's condition is androgen insensitivity syndrome, a genetic disorder in which the body is unable to respond to androgens, resulting in impaired virilization and development of male sex characteristics. In individuals with complete androgen insensitivity syndrome, the external genitalia appear female, but the internal reproductive organs are absent or underdeveloped.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The likely diagnosis for the patient's condition is ankylosing spondylitis.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The likely diagnosis for the patient's condition is colonic pseudo-obstruction, also known as Ogilvie syndrome.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The likely diagnosis for the patient's condition is diabetic ketoacidosis.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   The likely diagnosis for the patient's condition is fibromuscular dysplasia.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The likely diagnosis for the patient's condition is systemic lupus erythematosus (SLE).       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mnemonic caNNOT is used to remember the toxicities associated with aminoglycoside antibiotics. It stands for Nephrotoxicity, Neuromuscular blockade, Ototoxicity, and Teratogen (specifically, deafness in neonates).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The most common cause of mitral regurgitation in developed countries is mitral valve prolapse.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The term used to describe this type of disease prevention is secondary.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The type of leukemia that is commonly associated with Down syndrome is acute lymphoblastic leukemia, and it typically occurs after the age of 5 years.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            The virulence factor that is commonly found in these three bacterial species is IgA protease. This enzyme is capable of cleaving immunoglobulin A (IgA), which is an important component of the body's immune system, and can help these bacteria evade the host's immune response.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Thiazide diuretics block the Na+-Cl- cotransporter on the luminal membrane of the DCT.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Thiazide diuretics can be used to prevent calcium kidney stones.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Thiazide diuretics may be useful in the treatment of nephrogenic diabetes insipidus.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Thiazide diuretics stimulate the reabsorption of Ca2+ in the distal tubule of the kidney.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Thrombotic thrombocytopenic purpura (TTP) is caused by inhibition or deficiency of the ADAMTS13 (vWF metalloprotease) enzyme.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tizanidine is an α2 agonist that may be used as a muscle relaxant.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Topiramate is an anti-epileptic associated with weight loss.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Trazodone is an atypical antidepressant that is primarily used to treat insomnia.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Tumor Lysis Syndrome is most commonly associated with the treatment of lymphomas and acute lymphoblastic leukemia.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Type I collagen.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Type III collagen.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Upper motoneuron lesions may cause hyper-reflexia.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Upper motoneuron lesions may cause spastic paralysis.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           VIPoma is a rare type of neuroendocrine tumor that can cause a range of symptoms. However, it is typically characterized by a triad of watery diarrhea, hypokalemia (low potassium levels in the blood), and achlorhydria (low or absent stomach acid production). These symptoms can be caused by the excess production of vasoactive intestinal peptide (VIP), a hormone that regulates various bodily functions. VIPoma can be diagnosed through various imaging and laboratory tests, and treatment may involve surgery, medication, or other interventions depending on the severity and location of the tumor.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Wilms tumor, also known as nephroblastoma, typically presents with these features.       0.00      0.00      0.00         2\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Wilson disease is caused by an autosomal recessive defect in ATP-mediated hepatocyte copper transport.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Wilson disease may be treated with oral zinc or chelating agents (e.g. penicillamine, trientine).       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Wiskott-Aldrich syndrome is caused by a mutation in the WASp gene.       0.00      0.00      0.00         0\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Zollinger-Ellison syndrome is diagnosed with a positive secretin stimulation test.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        α-methyldopa is an α2 agonist that is primarily used to treat gestational hypertension.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  α-methyldopa.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-blockers may cause unopposed α1 agonism if given alone for cocaine toxicity or pheochromocytoma.       0.00      0.00      0.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        β-thalassemia is most commonly seen in individuals of African or Mediterranean descent.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             β-thalassemia is usually caused by gene mutations.       1.00      1.00      1.00         1\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           β-thalassemia mutations in β-globin genes result in absent (β0) or diminished (β+) production of the β-globin chain.       1.00      1.00      1.00         1\n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       accuracy                           0.73       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      macro avg       0.43      0.45      0.44       162\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   weighted avg       0.60      0.73      0.66       162\n\n","output_type":"stream"},{"output_type":"display_data","data":{"text/plain":"<Figure size 1200x800 with 2 Axes>","image/png":"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"},"metadata":{}}]},{"cell_type":"code","source":"","metadata":{},"execution_count":null,"outputs":[]}]}